Search on Site

Explore our comprehensive database of pharmaceutical news releases, press releases, events, and industry insights with ease. Effortlessly find relevant information tailored to your interests and stay updated on the latest developments in the pharmaceutical sector. Start searching now to uncover valuable insights and resources for your pharmaceutical endeavors.

New HCPCS Billing Code Enables Medicare Reimbursement for Lasix® ONYU When Furnished Incident to a Physician’s Service

SQ Innovation announced that the Centers for Medicare & Medicaid Services (CMS) has established a new Healthcare Common Procedure Coding System (HCPCS) Level II code, J1946 ("Injection, furosemide (Lasix ONYU), 1 mg"), for its product Lasix® ONYU...

Jarrow Formulas® Launches Gut & Protein Optimizer and NMN 300 mg to Support Protein Absorption, Cellular Energy, and Healthy Aging

Jarrow Formulas®, a leading formulator and supplier of science-backed nutritional supplements, announced the launch of two new products, expanding its portfolio with targeted nutritional support: Jarrow Formulas® Gut & Protein Optimizer, designed...

Abbott Launched the First and Only Ready-to-Feed Liquid Infant Formula Made with Whole Milk in the U.S. at a Price Similar to Its Existing Similac Powdered Formula

Parents looking for an infant formula made with whole milk now have a new option. Abbott announced the launch of Similac® 360 Total Care Made With Whole Milk—the first and only commercially sterile, ready-to-feed liquid infant formula made with...

U.S. FDA Approves Ziihera® (zanidatamab-hrii), With or Without Tislelizumab Plus Chemotherapy, for the First-Line Treatment of HER2-Positive Advanced Gastroesophageal Adenocarcinoma

Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera® (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive...

Neurolief Advances Veteran Mental Health and Migraine Care With New VA Contract for Prescription Neuromodulation

Neurolief, a neuroscience-driven medical technology company developing brain neuromodulation therapies for mental health and neurological conditions, is bringing two prescription therapies to U.S. veterans through a new Department of Veterans...

U.S. FDA Accepts sBLA for ENFLONSIA™ to Expand RSV Indication to High-Risk Children Under Two

Merck known as MSD outside of the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) for ENFLONSIA™ (clesrovimab-cfor) to expand its indication to...

Takeda's ORZEYFUL™ Receives U.S. FDA Approval for Narcolepsy Type 1

Takeda announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent...

Triquetra Health Launched BioActive Vitamin B1™—the First Complete B1 Activation System with a 600 mg Research-Matched Dose and Full Cofactor Support

Triquetra Health, a clinical-grade supplement company specializing in evidence-based formulation, announced the launch of BioActive Vitamin B1™ Clinical Strength, a complete B1 activation system delivering 600mg benfotiamine at the...

Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection in two single-dose vial strengths

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch1 of Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials. Glenmark's Sugammadex Injection is bioequivalent and therapeutically equivalent to...

EMS and BD expand access to GLP-1 therapies in Brazil by launching semaglutide.

BD a leading global medical technology company, and EMS, one of Brazil's leading pharmaceutical companies, announced their collaboration in the launch of a semaglutide therapy in Brazil. This collaboration and launch underscore a shared commitment...

Excedr Secures $25 Million in Growth Capital to Expand Its Life Sciences Equipment Leasing Platform

Excedr, Inc. a leading provider of full-service laboratory equipment leasing solutions for the life sciences and healthcare industries, announced the closing of $25 million in growth capital. The round includes a $17 million senior credit facility...

InstaMed® Pharmaceuticals Appoints Tracy Gibbs, PhD, as Chief Executive Officer Ahead of the Worldwide Launch of Its Non-Injectable Peptide Platform

InstaMed® Pharmaceuticals, an advanced biotechnology company transforming peptide delivery through its patented InstaRelease® oral dissolving strip platform, announced the appointment of Tracy Gibbs, PhD, as Chief Executive Officer. The leadership...

FDA Clears Roche's cobas® BV/CV Assay, Enabling Fast and Highly Accurate Diagnosis of Vaginitis

Roche announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its cobas® BV/CV (Bacterial vaginosis/Candida vaginitis) assay. This molecular diagnostic test provides results for both Bacterial vaginosis (BV) and...

China Approves Haisco's Class 1 Innovative Drug, Ciprocopan Succinate Tablets, Providing a New Treatment Option for Patients with PNH

Haisco Pharmaceutical Group claimed today their independently developed Class 1 innovative drug, Ciprocopan Succinate Tablets (development code: HSK39297), has received marketing approval from the National Medical Products Administration of China...

Virax Biolabs CEO James Foster Updates Shareholders Following the Fiscal 2026 Annual Report and Commercial Supply Agreement with Fosun Diagnostics

Virax Biolabs Group Limited a biotechnology company focused on immune response detection, T cell immune profiling and in vitro diagnostic technologies, today published a shareholder update from Chief Executive Officer James Foster providing...

Children's Hospital of Philadelphia Initiative Substantially Increases Naloxone Co-Prescribing When Prescribing Outpatient Opioids

A multidisciplinary team at Children's Hospital of Philadelphia (CHOP) substantially increased naloxone co-prescribing for patients prescribed outpatient opioid prescriptions through an enterprise-wide quality improvement initiative designed to...

Hologic’s Aptima® HPV Test Receives Expanded CE-IVDR Mark to Include Self-Collected Samples for Cervical Cancer Screening

Hologic, Inc. announced that its Aptima® HPV Assay received an expanded CE-IVDR marking in the European Union and the UK and is now approved for self-collected vaginal samples using the Aptima Multitest Specimen Collection Kit. Cervical cancer is...

Erbitux® (cetuximab) in Combination with Encorafenib and FOLFOX Approved by the European Commission as a First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

Merck, a leading global science and technology company, announced that the European Commission (EC) approved an update to the Erbitux (cetuximab) EU label on June 26, 2026. Erbitux is now indicated in combination with encorafenib for patients with...

BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO® (vosoritide) for Children With Achondroplasia Accepted by the U.S. Food and Drug Administration

BioMarin Pharmaceutical Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for VOXZOGO® (vosoritide) for full approval in children with achondroplasia. . "This...

FDA Approves Expanded Indication for Octapharma USA's wilate® for Prophylaxis of von Willebrand Disease in Children Younger Than 6 Years

On July 2, 2026, the U.S. Food and Drug Administration (FDA) approved the use of wilate® (von Willebrand Factor/Coagulation Factor VIII Complex [Human]) for routine prophylaxis to reduce the frequency of bleeding episodes in pediatric patients...